“…In addition, ET-1 (a vasoconstrictor peptide secreted from endothelial cell) is thought to play a pathological role in a number of vascular diseases (Goto et al, 1996). Interestingly, it was recently reported that ET-1 can activate PI3-K in several cells (Ishibashi et al, 2000;Kawanabe et al, 2003) and that ET-1 activates NAD(P)H oxidase and induces superoxide production in cultured endothelial and smooth muscle cells (Duerrschmidt et al, 2000;Wedgwood et al, NAD(P)H oxidase is increased in STZ-induced diabetic aortae (Kanie and Kamata, 2002) and that this increase is normalized by the endothelin antagonist, J-104132, suggesting that ET-1 is involved in the increased formation of superoxide anions. Furthermore, we found that chronic administration of a relatively low dose of bezafibrate, which was insufficient to alter the levels of plasma lipids (including total cholesterol, LDL cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride), exerted an improvement effect on the endothelial dysfunction seen in the aorta in rats with established STZ-induced diabetes.…”